Feng Biosciences 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tarvacin (bavituximab) / Feng Biosciences
2019-000949-13: A Study to investigate Bavituximab in combination with Pembrolizumab in patients with advanced gastric or gastroesophageal cancer.

Not yet recruiting
2
80
Europe
Bavituximab, Pembrolizumab, NA, Solution for infusion, Solution for injection, Keytruda
OncXerna Therapeutics, Inc., OncXerna Therapeutics, Inc.
Advanced gastric or gastroesophageal cancer that progressed on or after at least one prior standard therapy, Advanced gastric or gastroesophageal junction cancer that progressed on or after at least one prior standard therapy., Diseases [C] - Cancer [C04]
 
 
KEYNOTE 978, NCT04099641: An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

Completed
2
80
Europe, US, RoW
Bavituximab, Pembrolizumab Injection, Keytruda
OncXerna Theraputics, Inc., Merck Sharp & Dohme LLC
Gastric Cancer, GastroEsophageal Cancer
12/21
10/22
NCT03139916: Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Completed
2
36
US
Temozolomide, Temodar, Bavituximab, Radiation
Massachusetts General Hospital, Peregrine Pharmaceuticals, National Comprehensive Cancer Network
Glioblastoma
08/22
08/22
NCT03519997: A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Active, not recruiting
2
35
US
Pembrolizumab, Bavituximab
David Hsieh, Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
04/23
04/25
NCT04150900: 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Active, not recruiting
2
7
US
Bavituximab, Pembrolizumab
University of Maryland, Baltimore
Squamous Cell Carcinoma
09/24
01/27
lefitolimod (MGN1703) / Feng Biosciences, iPharma, Gilead
TITAN, NCT03837756 / 2018-001165-16: Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

Completed
2a
47
Europe, US, RoW
Saline, Lefitolimod, MGN1703, 3BNC117 and 10-1074, RUhumab-001 and RUhumab-002
University of Aarhus, Aalborg University Hospital, Odense University Hospital, Rigshospitalet, Denmark, Hvidovre University Hospital, The Peter Doherty Institute for Infection and Immunity, University of Utah, Oslo University Hospital
HIV-1-infection
07/22
05/23
NCT02532205: A Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Not yet recruiting
1
60
US
MGN1703, Ipilimumab, BMS-734016, Yervoy, MDX010
M.D. Anderson Cancer Center, Mologen AG
Advanced Cancers, Melanoma, Advanced Solid Malignancies
12/18
 
NCT02668770: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Checkmark Enrollment completion of P1 combinational trial with ipilimumab
Jul 2020 - Jul 2020: Enrollment completion of P1 combinational trial with ipilimumab
Hourglass Jan 2019 - Dec 2019 : In combination with Yervoy for advanced solid malignances
Hourglass Jan 2017 - Dec 2018 : Completion of recruitment (advanced solid malignancies)
Hourglass Sep 2018 - Dec 2018 : Completion of dose escalation portion of P1 trial for advanced solid malignancies
More
Active, not recruiting
1
28
US
MGN1703, Ipilimumab, BMS-734016, Yervoy, MDX010
M.D. Anderson Cancer Center, Mologen AG
Advanced Cancers, Melanoma
05/25
05/25
navicixizumab (OMP-305B83) / Feng Biosciences
2021-001933-38: Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Estudio de Navicixizumab con paclitaxel y navicixizumab en monoterapia en comparación con paclitaxel en monoterapia en pacientes con cáncer de ovario epitelial resistente al platino, peritoneal primario o de trompa de Falopio

Ongoing
3
400
Europe
Navicixizumab, OMP-305B83, Solution for infusion, Concentrate for solution for infusion, Paclitaxel AqVida 6 mg/ml concentrate for solution for infusion
OncXerna Therapeutics, Inc., OncXerna Therapeutics, Inc.
Patients With Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Pacientes con cáncer de ovario epitelial resistente al platino, peritoneal primario o de trompa de Falopio, Ovarian cancer Cáncer de ovario, Diseases [C] - Cancer [C04]
 
 
NCT05043402 / 2021-001933-38: A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer

Not yet recruiting
3
400
NA
navicixizumab, navi, Xerna™ TME Panel
OncXerna Theraputics, Inc., OncXerna Therapeutics, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
11/23
08/24
ONCX-NAV-G201, NCT05453825: A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

Recruiting
2
180
US
navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy
OncXerna Theraputics, Inc.
Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
04/24
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tarvacin (bavituximab) / Feng Biosciences
2019-000949-13: A Study to investigate Bavituximab in combination with Pembrolizumab in patients with advanced gastric or gastroesophageal cancer.

Not yet recruiting
2
80
Europe
Bavituximab, Pembrolizumab, NA, Solution for infusion, Solution for injection, Keytruda
OncXerna Therapeutics, Inc., OncXerna Therapeutics, Inc.
Advanced gastric or gastroesophageal cancer that progressed on or after at least one prior standard therapy, Advanced gastric or gastroesophageal junction cancer that progressed on or after at least one prior standard therapy., Diseases [C] - Cancer [C04]
 
 
KEYNOTE 978, NCT04099641: An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

Completed
2
80
Europe, US, RoW
Bavituximab, Pembrolizumab Injection, Keytruda
OncXerna Theraputics, Inc., Merck Sharp & Dohme LLC
Gastric Cancer, GastroEsophageal Cancer
12/21
10/22
NCT03139916: Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Completed
2
36
US
Temozolomide, Temodar, Bavituximab, Radiation
Massachusetts General Hospital, Peregrine Pharmaceuticals, National Comprehensive Cancer Network
Glioblastoma
08/22
08/22
NCT03519997: A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Active, not recruiting
2
35
US
Pembrolizumab, Bavituximab
David Hsieh, Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
04/23
04/25
NCT04150900: 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Active, not recruiting
2
7
US
Bavituximab, Pembrolizumab
University of Maryland, Baltimore
Squamous Cell Carcinoma
09/24
01/27
lefitolimod (MGN1703) / Feng Biosciences, iPharma, Gilead
TITAN, NCT03837756 / 2018-001165-16: Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

Completed
2a
47
Europe, US, RoW
Saline, Lefitolimod, MGN1703, 3BNC117 and 10-1074, RUhumab-001 and RUhumab-002
University of Aarhus, Aalborg University Hospital, Odense University Hospital, Rigshospitalet, Denmark, Hvidovre University Hospital, The Peter Doherty Institute for Infection and Immunity, University of Utah, Oslo University Hospital
HIV-1-infection
07/22
05/23
NCT02532205: A Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Not yet recruiting
1
60
US
MGN1703, Ipilimumab, BMS-734016, Yervoy, MDX010
M.D. Anderson Cancer Center, Mologen AG
Advanced Cancers, Melanoma, Advanced Solid Malignancies
12/18
 
NCT02668770: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Checkmark Enrollment completion of P1 combinational trial with ipilimumab
Jul 2020 - Jul 2020: Enrollment completion of P1 combinational trial with ipilimumab
Hourglass Jan 2019 - Dec 2019 : In combination with Yervoy for advanced solid malignances
Hourglass Jan 2017 - Dec 2018 : Completion of recruitment (advanced solid malignancies)
Hourglass Sep 2018 - Dec 2018 : Completion of dose escalation portion of P1 trial for advanced solid malignancies
More
Active, not recruiting
1
28
US
MGN1703, Ipilimumab, BMS-734016, Yervoy, MDX010
M.D. Anderson Cancer Center, Mologen AG
Advanced Cancers, Melanoma
05/25
05/25
navicixizumab (OMP-305B83) / Feng Biosciences
2021-001933-38: Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Estudio de Navicixizumab con paclitaxel y navicixizumab en monoterapia en comparación con paclitaxel en monoterapia en pacientes con cáncer de ovario epitelial resistente al platino, peritoneal primario o de trompa de Falopio

Ongoing
3
400
Europe
Navicixizumab, OMP-305B83, Solution for infusion, Concentrate for solution for infusion, Paclitaxel AqVida 6 mg/ml concentrate for solution for infusion
OncXerna Therapeutics, Inc., OncXerna Therapeutics, Inc.
Patients With Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Pacientes con cáncer de ovario epitelial resistente al platino, peritoneal primario o de trompa de Falopio, Ovarian cancer Cáncer de ovario, Diseases [C] - Cancer [C04]
 
 
NCT05043402 / 2021-001933-38: A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer

Not yet recruiting
3
400
NA
navicixizumab, navi, Xerna™ TME Panel
OncXerna Theraputics, Inc., OncXerna Therapeutics, Inc.
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
11/23
08/24
ONCX-NAV-G201, NCT05453825: A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

Recruiting
2
180
US
navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy
OncXerna Theraputics, Inc.
Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
04/24
12/24

Download Options